Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
JCO Global Oncology
|
March 8, 2023
Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis
Hamdy A Azim, Hagar Elghazawy, Ramy M Ghazy, et al.
Journal of Chemotherapy (Florence, Italy)
|
May 20, 2024
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
Hamdy A Azim, Mariam A Saleh, Passant Essam Eldin, et al.
Arab Journal of Gastroenterology : the Official Publication of the Pan-Arab Association of Gastroenterology
|
November 4, 2015
Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients
Mohamed Yehia Elbarmelgi, Ahmed Farag, Hamdy A Azim, et al.
Translational Oncology
|
April 17, 2016
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
Hamdy A Azim, Loay Kassem, Isabelle Treilleux, et al.
JCO Precision Oncology
|
August 6, 2025
Impact of <i>BRCA</i> Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Hamdy A Azim, Hagar Elghazawy, Kyrillus S Shohdy, et al.
BMC Cancer
|
September 26, 2012
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Nabil Mubarak, Rabab Gaafar, Samir Shehata, et al.
The Oncologist
|
June 27, 2025
Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy
Hagar Elghazawy, Mahmoud Elghazawy, Hamdy A Azim, et al.
The Oncologist
|
July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
Journal of Hepatocellular Carcinoma
|
December 5, 2018
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Hamdy A Azim, Ashraf Omar, Hesham Atef, et al.
Oncology and Therapy
|
September 21, 2023
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
Hamdy A Azim, Samah A Loutfy, Hatem A Azim, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
JCO Global Oncology
|
March 8, 2023
Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis
Hamdy A Azim, Hagar Elghazawy, Ramy M Ghazy, et al.
Journal of Chemotherapy (Florence, Italy)
|
May 20, 2024
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
Hamdy A Azim, Mariam A Saleh, Passant Essam Eldin, et al.
Arab Journal of Gastroenterology : the Official Publication of the Pan-Arab Association of Gastroenterology
|
November 4, 2015
Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients
Mohamed Yehia Elbarmelgi, Ahmed Farag, Hamdy A Azim, et al.
Translational Oncology
|
April 17, 2016
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
Hamdy A Azim, Loay Kassem, Isabelle Treilleux, et al.
JCO Precision Oncology
|
August 6, 2025
Impact of <i>BRCA</i> Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Systematic Review and Meta-Analysis
Hamdy A Azim, Hagar Elghazawy, Kyrillus S Shohdy, et al.
BMC Cancer
|
September 26, 2012
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Nabil Mubarak, Rabab Gaafar, Samir Shehata, et al.
The Oncologist
|
June 27, 2025
Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy
Hagar Elghazawy, Mahmoud Elghazawy, Hamdy A Azim, et al.
The Oncologist
|
July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
Journal of Hepatocellular Carcinoma
|
December 5, 2018
Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Hamdy A Azim, Ashraf Omar, Hesham Atef, et al.
Oncology and Therapy
|
September 21, 2023
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
Hamdy A Azim, Samah A Loutfy, Hatem A Azim, et al.
Page
of 4